Zymeworks Inc. (NYSE:ZYME) Director Buys $168,846.96 in Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 11,958 shares of the firm’s stock in a transaction on Tuesday, December 24th. The shares were acquired at an average price of $14.12 per share, with a total value of $168,846.96. Following the completion of the purchase, the director now owns 14,704,239 shares in the company, valued at approximately $207,623,854.68. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The stock was acquired at an average price of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Stock Performance

NYSE:ZYME opened at $14.50 on Monday. The stock has a market capitalization of $998.73 million, a PE ratio of -9.67 and a beta of 1.12. Zymeworks Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $17.70. The company has a fifty day moving average of $14.27 and a two-hundred day moving average of $12.05.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm had revenue of $16.00 million for the quarter, compared to analyst estimates of $17.90 million. During the same period last year, the company posted ($0.41) EPS. Zymeworks’s quarterly revenue was down 3.1% compared to the same quarter last year. Research analysts forecast that Zymeworks Inc. will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 price target on shares of Zymeworks in a report on Friday, November 22nd. Stifel Nicolaus raised their target price on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, October 28th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target for the company in a report on Monday, December 16th. Citigroup raised their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Finally, Leerink Partners upgraded shares of Zymeworks from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $10.00 to $25.00 in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Zymeworks presently has an average rating of “Moderate Buy” and a consensus target price of $19.17.

Institutional Trading of Zymeworks

A number of institutional investors have recently made changes to their positions in ZYME. Perceptive Advisors LLC raised its stake in Zymeworks by 55.2% in the 2nd quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company’s stock valued at $14,192,000 after purchasing an additional 592,904 shares during the last quarter. Rubric Capital Management LP grew its holdings in shares of Zymeworks by 12.7% during the second quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company’s stock worth $33,336,000 after buying an additional 441,947 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Zymeworks by 127.5% during the second quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company’s stock worth $6,090,000 after buying an additional 401,068 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Zymeworks in the third quarter valued at about $4,156,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Zymeworks in the second quarter worth about $1,683,000. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.